Q-omics provides the consensus-scored C7orf65 profile across patient tissues and cancer cell-line models. C7orf65 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, C7orf65 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, C7orf65 RNA expression shows 8,628 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KIRC, and TGCT as cancer lineages where C7orf65 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C7orf65 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C7orf65 survival associations across molecular data types. C7orf65 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C7orf65 RNA expression–survival associations across cancer types. High C7orf65 expression shows unfavorable associations in UCEC, ACC, KIRP, CHOL and LUSC, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for C7orf65 RNA expression.
This table summarizes C7orf65 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C7orf65. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C7orf65 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, BLCA, LUSC and CHOL. The KIRC box plot shows higher C7orf65 RNA expression in tumor versus normal tissue (log2 FC = +0.071, t-test p < 0.001).
This table shows molecular features associated with C7orf65 in patient tissues and cancer cell lines. In patient samples, C7orf65 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C7orf65 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
